Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
ApexOnco Front Page
Recent articles
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
Starglo isn't applicable to a US population, an adcom rules.
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
PF-08046037 joins PF-08046054 in clinical development.
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
RPCAR01 starts a phase 1 study, albeit one sponsored by academics.
